Solid Biosciences Inc. Other Non-Current Liabilities
Solid Biosciences Inc. (SLDB) had Other Non-Current Liabilities of $96.00 thousand as of 2022-12-31, per its 10-K filed 2024-03-13.
Discontinued › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OtherLiabilitiesNoncurrent · last filed 2024-03-13
- 2022-12-31: Other Liabilities, Noncurrent $96.00K.
- 2020-12-31: Other Liabilities, Noncurrent $1.30M.
- 2018-12-31: Other Liabilities, Noncurrent $1.07M.
- 2018-09-30: Other Liabilities, Noncurrent $1.10M.
| Period end | Other Liabilities, Noncurrent |
|---|---|
| 2022-12-31 | $96.00K 10-K · filed 2024-03-13 |
| 2020-12-31 | $1.30M 10-K · filed 2022-03-14 |
| 2018-12-31 | $1.07M 10-K · filed 2020-03-12 |
| 2018-09-30 | $1.10M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $499.00K 10-Q · filed 2018-08-10 |
| 2018-03-31 | $365.00K 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |